Galectin Therapeutics, Inc. (GALT)

3.5000 -0.0100 (-0.28%) At close: 04:00PM EDT

Galectin Therapeutics, Inc.

4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
(678) 620-3186
https://galectintherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 28

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Joel Lewis	President, CEO & Director	907.72k	N/A	1970
Mr. Jack W. Callicutt CPA	CFO, Treasurer & Corporate Secretary	521.47k	N/A	1967
Dr. Pol F. Boudes M.D., Ph.D.	Chief Medical Officer	730.33k	N/A	1957
Robert Tritt	General Counsel	N/A	N/A	N/A
Mr. Jeff Katstra	Head of CMC & Pharmaceutical Development	N/A	N/A	N/A
Ms. Beth Knowles	Executive Assistant & Officer Manager	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Corporate governance

Galectin Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.